Cytokine inducible SH2 containing protein (CIS; encoded by the gene CISH) is a member of the suppressor of cytokine signaling (SOCS) family of proteins.

Under the terms of the agreement, ONK secured exclusive global rights to WEHI's patent covering the use of human NK cells lacking the CISH gene for the purposes of researching, developing, manufacturing, and commercializing NK cell therapies.

The financial terms of the agreement include milestone payments and royalties on sales, but specifics were not disclosed.

CRISPR Therapeutics, Nkarta partner on gene edited cancer therapies
CRISPR Therapeutics has established a strategic partnership with Nkarta to research, develop, and commercialize CRISPR/Cas9 gene edited cell therapies...

CytoImmune, City of Hope ink CAR-NK cell therapy agreements
CytoImmune Therapeutics and City of Hope plan to collaborate on a portfolio of chimeric antigen receptor (CAR)-natural killer (NK) cell therapies through...

Cytovia ramps up production of NK cells ahead of trials
Cytovia Therapeutics has signed two agreements for research and development and manufacturing operations to move the company's chimeric antigen receptor-natural...

ONK strengthens cell therapy manufacturing capabilities
ONK Therapeutics has entered into a license agreement with the U.S. National Institutes of Health to gain rights to make and use clinically validated...

ONK licenses 3 NK cell therapy products
ONK Therapeutics has signed three licensing agreements for natural killer (NK) cell therapy products.